iShares Core MSCI Taiwan Index ETF (03074.HK) Rises 1.67% Intraday, NAV at HKD 482.728
NewTimeSpace News: As of 13:54 on June 18, iShares Core MSCI Taiwan Index ETF (03074.HK) rose 1.67%, standing at HKD 493.900.
NewTimeSpace News: As of 13:54 on June 18, iShares Core
MSCI Taiwan Index ETF (03074.HK) stood at HKD 493.900, up 1.67%. The ETF opened today at HKD 488.600, with the latest Net Asset Value (NAV) at HKD 482.728 and a premium rate of 0.64%. The ETF recorded a turnover of approximately HKD 7.579 million and an average price of HKD 491.188, with total Assets Under Management (AUM) of approximately HKD 1.004 billion.
iShares Core MSCI Taiwan Index ETF (03074.HK) closely tracks the MSCI Taiwan Index. The index covers representative large- and mid-cap companies in the Taiwan market, broadly reflecting the overall performance of Taiwan equities.
iShares Core MSCI Taiwan Index ETF (03074.HK) closely tracks the MSCI Taiwan Index. The index covers representative large- and mid-cap companies in the Taiwan market, broadly reflecting the overall performance of Taiwan equities.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags:
- SHENYANG PUBLIC (00747.HK): Disposes of 100% Equity Interest in Target Company for RMB 2 Million, Expects Gain of About RMB 33.55 Million
- NEWLINK TECH (09600.HK): Termination of Memorandum of Intent on Equity Acquisition; Proposed Acquisition Will Not Proceed
- Going Global Weekly: Mainland Companies Flock to Hong Kong Listings, Pharma Globalisation Shifts to Data and Capability Export-20260918
- IMPACT THERAP-B (07630.HK): Sepalna Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Ovarian Cancer
- CISI FIN (06058.HK): Discloseable Transaction — Subsidiary Disposes of USD 20.15 Million Notes, Recording a Gain of About USD 165,407